News
Impax Asset Management significantly reduced its position in Regeneron Pharmaceuticals by 53% in the first quarter, selling 1 ...
Leerink Partnrs has cut its Q3 2025 earnings estimate for Regeneron Pharmaceuticals, citing lowered expectations across the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback